Skip to Content
Merck
All Photos(1)

Documents

EMU154511

Sigma-Aldrich

MISSION® esiRNA

targeting mouse Erbb3

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CCCCGTGAAGTCAAGAATTTCCACCTTTTCTCAAACAAAAAACCATTTCTTTGACACATTTGAATTAATAGCAGGACTTGCCCTTTGGGCCCATTCTTAGGTAAGATGAGGGTCTTTGAGCACAAGTACTATGAGATCTGTCAGTCAATCTAATAACCAGGCAGGTAATTAAGTGGCTCAAGAGCAAATAGGTTATTCAGTGCGGGTGTACCAGGCAGAGATGATTCATCTACCAAGTGGAACAGGAGAGGCCGGCTGTGATTTCATCGTGCTATTCAGAATGGGTACTATGTAAACTGTAAGGATTATTTATTTCAGGAACTTGTCACTCAGCATGTTTCAGATGACAGTTGACCACAGGTTACTAAAACTGTGGACAGCAAAACCTCAGAAAATGGGGAATTGAGCCTTGAAGAAGCAAAGCCACAGGTCCAGGATTCAAAATCCTCCCAATTCCCATGCCTGTGATTTAACTATAAAGTGTATGTGTGTGTGTGTAAAGCCGGGCCT

Ensembl | mouse accession no.

NCBI accession no.

shipped in

ambient

storage temp.

−20°C

Gene Information

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C He et al.
Oncogene, 34(50), 6040-6054 (2015-03-24)
Mechanisms underlying ovarian cancer initiation and progression are unclear. Herein, we report that the Yes-associated protein (YAP), a major effector of the Hippo tumor suppressor pathway, interacts with ERBB signaling pathways to regulate the initiation and progression of ovarian cancer.
Maicol Mancini et al.
Science signaling, 8(379), ra53-ra53 (2015-06-04)
Despite initial responses to targeted kinase inhibitors, lung cancer patients presenting with primary epidermal growth factor receptor (EGFR) mutations acquire resistance, often due to a second-site mutation (T790M). However, clinical trials found no survival benefits in patients treated with a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service